Activation of the nuclear receptor PPARα regulates lipid metabolism in foetal liver from diabetic rats: Implications in diabetes-induced foetal overgrowth

Diabetes/Metabolism Research and Reviews

Volumn 27, Issue 1, 2011, Pages 35-46

  Martínez, Nora ^a   White, Verónica ^a   Kurtz, Melisa ^a   Higa, Romina ^a   Capobianco, Evangelina ^a   Jawerbaum, Alicia ^a  

^a Centre de Estudios Farmacologicos y Botanicos   (Argentina)

Author keywords

Diabetes; Foetus; Lipid metabolism; Liver; PPAR; Pregnancy

Indexed keywords

CHOLESTEROL; CHOLESTEROL ESTER; CLOFIBRATE; GLUCOSE; LEUKOTRIENE B4; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PHOSPHOLIPID; THIOBARBITURIC ACID REACTIVE SUBSTANCE; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; FETUS; FETUS GROWTH; FETUS OVERGROWTH; GESTATION PERIOD; LIPID LIVER LEVEL; LIPID METABOLISM; LIPID PEROXIDATION; LIPOGENESIS; LIVER METABOLISM; LIVER WEIGHT; MATERNAL DIABETES MELLITUS; METABOLIC PARAMETERS; METABOLIC REGULATION; NONHUMAN; PRIORITY JOURNAL; RAT; STREPTOZOCIN DIABETES;

ANIMALS; BODY WEIGHT; CELL NUCLEUS; DIABETES MELLITUS, EXPERIMENTAL; FEMALE; FETUS; LEUKOTRIENE B4; LIPID METABOLISM; LIPID PEROXIDATION; LIVER; PPAR ALPHA; PREGNANCY; RATS; RATS, WISTAR; TRIGLYCERIDES;

EID: 78651066781     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.1151     Document Type: Article

References (65)

1. Michael Weindling A. Offspring of diabetic pregnancy: short-term outcomes. Semin Fetal Neonatal Med 2009; 14: 111-118.
2. Jansson T, Cetin I, Powell TL, et al. Placental transport and metabolism in fetal overgrowth-a workshop report. Placenta 2006; 27(Suppl A): S109-S113.
3. Jawerbaum A, White V. Animal models in diabetes and pregnancy. Endocrine Rev 2010; 31: 680-701.
4. Cetin I, Radaelli T. Normal and abnormal fetal growth. In Diabetology of Pregnancy, Djelmis J, Desoye G, Ivanisevie M (eds). Karger: Basel, 2005; 72-82.
5. Reece EA, Leguizamon G, Wiznitzer A. Gestational diabetes: the need for a common ground. Lancet 2009; 373: 1789-1797.
6. Susa JB, McCormick KL, Widness JA, et al. Chronic hyperinsulinemia in the fetal rhesus monkey: effects on fetal growth and composition. Diabetes 1979; 28: 1058-1063.
7. Herrera E, Amusquivar E. Lipid metabolism in the fetus and the newborn. Diabetes Metab Res Rev 2000; 16: 202-210.
8. Catalano PM, Kirwan JP, Haugel-de Mouzon S, King J. Gestational diabetes and insulin resistance: role in short- and long-term implications for mother and fetus. J Nutr 2003; 133: 1674S-1683S.
9. McCurdy CE, Bishop JM, Williams SM, et al. Maternal high-fat diet triggers lipotoxicity in the fetal livers of nonhuman primates. J Clin Invest 2009; 119: 323-335.
10. Schaefer-Graf UM, Graf K, Kulbacka I, et al. Maternal lipids as strong determinants of fetal environment and growth in pregnancies with gestational diabetes mellitus. Diabetes Care 2008; 31: 1858-1863.
11. Khan NA. Role of lipids and fatty acids in macrosomic offspring of diabetic pregnancy. Cell Biochem Biophys 2007; 48: 79-88.
12. Herrera E, Amusquivar E, Lopez-Soldado I, Ortega H. Maternal lipid metabolism and placental lipid transfer. Horm Res 2006; 65((Suppl 3)): 59-64.
13. Shafrir E, Khassis S. Maternal-fetal fat transport versus new fat synthesis in the pregnant diabetic rat. Diabetologia 1982; 22: 111-117.
14. Reddy JK, Rao MS. Lipid metabolism and liver inflammation. II. Fatty liver disease and fatty acid oxidation. Am J Physiol Gastrointest Liver Physiol 2006; 290: G852-G858.
15. Zimmermann T, Hummel L, Wagner H. Quantitative studies on the fetal lipid metabolism in rats: liver fatty acid esterification and conversion into carbon dioxide, and hepatic output of triglycerides and phospholipids into serum. Biol Neonate 1986; 49: 43-50.
16. Detmer A, Carter AM, Thomas CR. The metabolism of free fatty acids and triacylglycerols by the fetal liver in a guinea pig model of intrauterine growth retardation. Pediatr Res 1992; 32: 441-446.
17. Lopez-Soldado I, Herrera E. Different diabetogenic response to moderate doses of streptozotocin in pregnant rats, and its long-term consequences in the offspring. Exp Diabesity Res 2003; 4: 107-118.
18. Cederberg J, Basu S, Eriksson UJ. Increased rate of lipid peroxidation and protein carbonylation in experimental diabetic pregnancy. Diabetologia 2001; 44: 766-774.
19. Min Y, Lowy C, Ghebremeskel K, et al. Unfavorable effect of type 1 and type 2 diabetes on maternal and fetal essential fatty acid status: a potential marker of fetal insulin resistance. Am J Clin Nutr 2005; 82: 1162-1168.
20. Jawerbaum A, Gonzalez E. Diabetic pregnancies: the challenge of developing in a pro-inflammatory environment. Curr Med Chem 2006; 13: 2127-2138.
21. Hihi AK, Michalik L, Wahli W. PPARs: transcriptional effectors of fatty acids and their derivatives. Cell Mol Life Sci 2002; 59: 790-798.
22. Lin Q, Ruuska SE, Shaw NS, Dong D, Noy N. Ligand selectivity of the peroxisome proliferator-activated receptor alpha. Biochemistry 1999; 38: 185-190.
23. Narala VR, Adapala RK, Suresh MV, et al. Leukotriene B4 is a physiologically relevant endogenous peroxisome proliferator-activated receptor-α agonist. J Biol Chem 2010; 285: 22067-22074.
24. Issemann I, Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 1990; 347: 645-650.
25. Beaven SW, Tontonoz P. Nuclear receptors in lipid metabolism: targeting the heart of dyslipidemia. Annu Rev Med 2006; 57: 313-329.
26. Lefebvre P, Chinetti G, Fruchart JC, Staels B. Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasis. J Clin Invest 2006; 116: 571-580.
27. Rakhshandehroo M, Sanderson LM, Matilainen M, et al. Comprehensive analysis of PPARalpha-dependent regulation of hepatic lipid metabolism by expression profiling. PPAR Res 2007; 2007: 26839.
28. Kallwitz ER, McLachlan A, Cotler SJ. Role of peroxisome proliferators-activated receptors in the pathogenesis and treatment of nonalcoholic fatty liver disease. World J Gastroenterol 2008; 14: 22-28.
29. Desvergne B, Michalik L, Wahli W. Be fit or be sick: peroxisome proliferator-activated receptors are down the road. Mol Endocrinol 2004; 18: 1321-1332.
30. Kersten S, Wahli W. Peroxisome proliferator activated receptor agonists. Exs 2000; 89: 141-151.
31. Panadero MI, Gonzalez MC, Herrera E, Bocos C. Factors modulating fibrates response: therapeutic implications and alternative strategies. Endocr Metab Immune Disord Drug Targets 2009; 9: 219-236.
32. Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev 1999; 20: 649-688.
33. Portha B, Picon L, Rosselin G. Chemical diabetes in the adult rat as the spontaneous evolution of neonatal diabetes. Diabetologia 1979; 17: 371-377.
34. Pustovrh MC, Capobianco E, Martinez N, et al. MMP/TIMP balance is modulated in vitro by 15dPGJ(2) in fetuses and placentas from diabetic rats. Eur J Clin Invest 2009; 39: 1082-1090.
35. Martinez N, Capobianco E, White V, et al. Peroxisome proliferator-activated receptor alpha activation regulates lipid metabolism in the feto-placental unit from diabetic rats. Reproduction 2008; 136: 95-103.
36. Capobianco E, White V, Higa R, Martinez N, Jawerbaum A. Effects of natural ligands of PPARgamma on lipid metabolism in placental tissues from healthy and diabetic rats. Mol Hum Reprod 2008; 14: 491-499.
37. Pustovrh MC, Jawerbaum A, Capobianco E, et al. Oxidative stress promotes the increase of matrix metalloproteinases-2 and -9 activities in the feto-placental unit of diabetic rats. Free Radic Res 2005; 39: 1285-1293.
38. Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 1979; 95: 351-358.
39. Pickard MR, Leonard AJ, Ogilvie LM, et al. Maternal hypothyroidism in the rat influences placental and liver glycogen stores: fetal growth retardation near term is unrelated to maternal and placental glucose metabolic compromise. J Endocrinol 2003; 176: 247-255.
40. Hay WW Jr. Placental-fetal glucose exchange and fetal glucose metabolism. Trans Am Clin Climatol Assoc 2006; 117: 321-339.
41. Lesage J, Hahn D, Leonhardt M, et al. Maternal undernutrition during late gestation-induced intrauterine growth restriction in the rat is associated with impaired placental GLUT3 expression, but does not correlate with endogenous corticosterone levels. J Endocrinol 2002; 174: 37-43.
42. Kamei Y, Tsutsumi O, Yamakawa A, et al. Maternal epidermal growth factor deficiency causes fetal hypoglycemia and intrauterine growth retardation in mice: possible involvement of placental glucose transporter GLUT3 expression. Endocrinology 1999; 140: 4236-4243.
43. Illsley NP, Caniggia I, Zamudio S. Placental metabolic reprogramming: do changes in the mix of energy-generating substrates modulate fetal growth? Int J Dev Biol 2010; 54: 409-419.
44. Soulimane-Mokhtari NA, Guermouche B, Yessoufou A, et al. Modulation of lipid metabolism by n-3 polyunsaturated fatty acids in gestational diabetic rats and their macrosomic offspring. Clin Sci (Lond) 2005; 109: 287-295.
45. Grissa O, Ategbo JM, Yessoufou A, et al. Antioxidant status and circulating lipids are altered in human gestational diabetes and macrosomia. Transl Res 2007; 150: 164-171.
46. Viana M, Aruoma OI, Herrera E, Bonet B. Oxidative damage in pregnant diabetic rats and their embryos. Free Radic Biol Med 2000; 29: 1115-1121.
47. Kinalski M, Sledziewski A, Telejko B, Zarzycki W, Kinalska I. Lipid peroxidation and scavenging enzyme activity in streptozotocin-induced diabetes. Acta Diabetol 2000; 37: 179-183.
48. Styrud J, Thunberg L, Nybacka O, Eriksson U J. Correlations between maternal metabolism and deranged development in the offspring of normal and diabetic rats. Pediatr Res 1995; 37: 343-353.
49. Ezekwe MO, Ezekwe EI, Sen DK, Ogolla F. Effects of maternal streptozotocin-diabetes on fetal growth, energy reserves and body composition of newborn pigs. J Anim Sci 1984; 59: 974-980.
50. Forman BM, Chen J, Evans RM. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. Proc Natl Acad Sci U S A 1997; 94: 4312-4317.
51. Krey G, Braissant O, L'Horset F, et al. Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay. Mol Endocrinol 1997; 11: 779-791.
52. Narala VR, Adapala RK, Suresh MV, Brock TG, Peters-Golden M, Reddy RC. Leukotriene B4 is a physiologically relevant endogenous peroxisome proliferator-activated receptor-α agonist. J Biol Chem 2010; 285: 22067-22074.
53. Soria A, Gonzalez Mdel C, Vidal H, Herrera E, Bocos C. Triglyceridemia and peroxisome proliferator-activated receptor-alpha expression are not connected in fenofibrate-treated pregnant rats. Mol Cell Biochem 2005; 273: 97-107.
54. Peraza MA, Burdick AD, Marin HE, Gonzalez FJ, Peters JM. The toxicology of ligands for peroxisome proliferator-activated receptors (PPAR). Toxicol Sci 2006; 90: 269-295.
55. Sugden MC, Greenwood GK, Smith ND, Holness MJ. Peroxisome proliferator-activated receptor-alpha activation during pregnancy attenuates glucose-stimulated insulin hypersecretion in vivo by increasing insulin sensitivity, without impairing pregnancy-induced increases in beta-cell glucose sensing and responsiveness. Endocrinology 2003; 144: 146-153.
56. Ringseis R, Gutgesell A, Dathe C, Brandsch C, Eder K. Feeding oxidized fat during pregnancy up-regulates expression of PPARalpha-responsive genes in the liver of rat fetuses. Lipids Health Dis 2007; 6: 6.
57. Hostetler HA, Petrescu AD, Kier AB, Schroeder F. Peroxisome proliferator-activated receptor alpha interacts with high affinity and is conformationally responsive to endogenous ligands. J Biol Chem 2005; 280: 18667-18682.
58. Schaiff WT, Carlson MG, Smith SD, et al. Peroxisome proliferator-activated receptor-gamma modulates differentiation of human trophoblast in a ligand-specific manner. J Clin Endocrinol Metab 2000; 85: 3874-3881.
59. Hein GJ, Bernasconi AM, Montanaro MA, et al. Nuclear receptors and hepatic lipidogenic enzyme response to a dyslipidemic sucrose-rich diet and its reversal by fish oil n-3 polyunsaturated fatty acids. Am J Physiol Endocrinol Metab 2010; 298: E429-E439.
60. van Straten E, van Meer H, Huijkman N, et al. Fetal liver X receptor activation acutely induces lipogenesis, but does not affect plasma lipid response to a high-fat diet in adult mice. Am J Physiol Endocrinol Metab 2009; 279: E1171-E1178.
61. Bensinger SJ, Tontonoz P. Integration of metabolism and inflammation by lipid-activated nuclear receptors. Nature 2008; 454: 470-477.
62. Belfort R, Berria R, Cornell J, Cusi K. Fenofibrate reduces systemic inflammation markers independent of its effects on lipid and glucose metabolism in patients with the metabolic syndrome. J Clin Endocrinol Metab 2010; 95: 829-836.
63. Anwer T, Sharma M, Pillai KK, et al. Protective effect of bezafibrate on streptozotocin-induced oxidative stress and toxicity in rats. Toxicology 2007; 229: 165-172.
64. Nakano S, Nagasawa T, Ijiro T, et al. Bezafibrate prevents hepatic stellate cell activation and fibrogenesis in a murine steatohepatitis model, and suppresses fibrogenic response induced by transforming growth factor-beta1 in a cultured stellate cell line. Hepatol Res 2008; 38: 1026-1039.
65. Yessoufou A, Soulaimann N, Merzouk SA, et al. N-3 fatty acids modulate antioxidant status in diabetic rats and their macrosomic offspring. Int J Obes (Lond) 2006; 30: 739-750.